Article

Identification of a Novel Raf-1 Pathway Activator that Inhibits Gastrointestinal Carcinoid Cell Growth

Endocrine Surgery Research Laboratory, University of Wisconsin, and the University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA.
Molecular Cancer Therapeutics (Impact Factor: 5.68). 02/2010; 9(2):429-37. DOI: 10.1158/1535-7163.MCT-09-0718
Source: PubMed

ABSTRACT

Carcinoids are neuroendocrine tumors (NET) that secrete hormones, including serotonin, resulting in the malignant carcinoid syndrome. In addition to the significant morbidity associated with the syndrome, carcinoids are frequently metastatic at diagnosis, and untreated mortality at 5 years exceeds 70%. Surgery is the only curative option, and the need for other therapies is clear. We have previously shown that activation of Raf-1 inhibits carcinoid cell proliferation. We investigated the ability of leflunomide (LFN), a Food and Drug Administration-approved medication for the treatment of rheumatoid arthritis, and its active metabolite teriflunomide (TFN) as a potential anti-NET treatment. LFN and TFN inhibit the in vitro proliferation of gastrointestinal carcinoid cells and induce G(2)-M phase arrest. Daily oral gavage of nude mice with subcutaneous xenografted carcinoid tumors confirms that LFN can inhibit NET growth in vivo. Treatment with TFN suppresses the cellular levels of serotonin and chromogranin A, a glycopeptide co-secreted with bioactive hormones. Additionally, TFN reduces the level of achaete-scute complex-like 1 (ASCL1), a NET marker correlated with survival. These effects are associated with the activation of the Raf-1/mitiogen-activated protein kinase kinase/extracellular signal-regulated kinase-1/2 pathway, and blockade of mitiogen-activated protein kinase kinase signaling reversed the effects of TFN on markers of the cell cycle and ASCL1 expression. In summary, LFN and TFN inhibit carcinoid cell proliferation in vitro and in vivo and alter the expression of NET markers. This compound thus represents an attractive target for further clinical investigation.

Download full-text

Full-text

Available from: Mackenzie Cook, Jan 10, 2014
    • "Table 1 RAF-1 activators in NENs (LFN, leflunomide; TFN, teriflunomide (active metabolite of leflunomide); MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) rapid colorimetric assay (MTT – Sigma Aldrich, St. Louis Mo) to measured cellular growth; ASCL1, achaete-scute homolog 1; CgA, chromogranin A; GSK-3b, Glycogen synthase kinase-3b; MTC, medullary thyroid cancer; TTY, tautomycin; TMC, tautomycetin; ZM336372, a novel Raf-1-activating agent; hASH1, human achaete-scute homolog). Authors Type of study Cell lines Drugs Methods (cell viability) Results in vitro/in vivo Biomarkers results Cook et al., Mol Cancer Ther [42] Preclinical – Human GI carcinoid cancer cells (BON) – Human broncho- pulmonary carcinoid tumor cells LFN -TFN MTT colorimetric assay; NET xenograft; western blot In vitro and in vivo inhibition human GI carcinoid cells tumor cell growth (dose dependent) Suppression of CgA, ASCL1 protein, and serotonin Pinchot et al., Am J Surg [43] Preclinical – Human GI carcinoid cancer cells (BON) – Human broncho- pulmonary carcinoid tumor cells TTY MTT colorimetric assay; western blot In vitro inhibition carcinoid tumor cell growth (dose dependent) Reduction of CgA level Adler et al., Mol Cancer Ther [44] Preclinical Human MTC cells TTY, TMC MTT colorimetric assay; western blot; calcitonin ELISA kit In vitro inhibition MTC cell growth (dose dependent) Reduction of CgA, ASCL1 protein level Van Gompel et al., Mol Cancer Ther [45] Preclinical – Human pulmonary carcinoid cells – Human pancreatic carcinoid tumor cells ZM336372 MTT colorimetric assay; western blot In vitro suppression cell proliferation (dose dependent) Reduction of CgA, hASH1 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Neuroendocrine neoplasms are a low-incidence and heterogeneous group of malignancies. In the advanced stage, several therapeutic options can be discussed, including molecular-targeted agents, but biological predicting factors are lacking. A number of molecular targets have been studied over the last decade leading to several phase II studies; however, very few agents progressed to phase III clinical trials. The RAF family of proteins belongs to the mitogen-activated protein kinase (MAPK) pathway, that has a role in several types of cancers, particularly related to BRAF mutations. Indeed BRAF inhibitors have been reported as being effective, mainly in melanoma. However, in neuroendocrine neoplasms BRAF mutations are extremely rare and RAF-1 activation has been reported to inhibit tumor growth in a pre-clinical setting. Therefore, in this field, RAF-1 activators rather than BRAF inhibitors should be clinically investigated. This article reviews the basic science as well as clinical data of RAF signaling in advanced neuroendocrine neoplasms with special emphasis on the potential role of both RAF activators and inhibitors.
    No preview · Article · Jun 2014 · Cancer Treatment Reviews
  • Source
    • "Interestingly, this effect could be inhibited by MEK inhibitors that, however, did not influence ERK1/2 phosphorylation, implicating an ERK1/2-independent pathway (Sippel et al. 2003a,b). While Sippel et al. (2003b) found that RAF1 activation did not to influence human pancreatic (BON) NET cell growth, other studies suggested that the RAF1 activator ZM336372 (as well as the drugs leflunomide and teriflunomide – both also associated with RAF1 pathway activation) suppressed the growth of human pulmonary (H727) and human pancreatic (BON) NET cells in vitro; for leflunomide and teriflunomide, this was also shown in vivo (Van Gompel et al. 2005, Cook et al. 2010). The in vivo reduction in development and growth of human medullary thyroid carcinomas through RAF1 activation has also been reported (Vaccaro et al. 2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Currently, there is no completely effective therapy available for metastatic phaeochromocytomas (PCCs) and paragangliomas. In this study, we explore new molecular targeted therapies for these tumours, using one more benign (mouse phaeochromocytoma cell (MPC)) and one more malignant (mouse tumour tissue (MTT)) mouse PCC cell line - both generated from heterozygous neurofibromin 1 knockout mice. Several PCC-promoting gene mutations have been associated with aberrant activation of PI3K/AKT, mTORC1 and RAS/RAF/ERK signalling. We therefore investigated different agents that interfere specifically with these pathways, including antagonism of the IGF1 receptor by NVP-AEW541. We found that NVP-AEW541 significantly reduced MPC and MTT cell viability at relatively high doses but led to a compensatory up-regulation of ERK and mTORC1 signalling at suboptimal doses while PI3K/AKT inhibition remained stable. We subsequently investigated the effect of the dual PI3K/mTORC1/2 inhibitor NVP-BEZ235, which led to a significant decrease of MPC and MTT cell viability at doses below 50 nM but again increased ERK signalling. Accordingly, we next examined the combination of NVP-BEZ235 with the established agent lovastatin, as this has been described to inhibit ERK signalling. Lovastatin alone significantly reduced MPC and MTT cell viability at therapeutically relevant doses and inhibited both ERK and AKT signalling, but increased mTORC1/p70S6K signalling. Combination treatment with NVP-BEZ235 and lovastatin showed a significant additive effect in MPC and MTT cells and resulted in inhibition of both AKT and mTORC1/p70S6K signalling without ERK up-regulation. Simultaneous inhibition of PI3K/AKT, mTORC1/2 and ERK signalling suggests a novel therapeutic approach for malignant PCCs.
    Full-text · Article · Jun 2012 · Journal of Molecular Endocrinology
  • Source
    • "GnrH receptors and the associated Raf-1/MEK/ERK-1/2-pathway are potential targets for analogs in cancer treatment. Activation of the Raf-1/MEK/ERK-1/2-pathway by leflunomide and teriflunomide can inhibit proliferation and growth of BON carcinoid cells in vitro and in vivo and also decrease expression of neuroendocrine markers in both BON and H727 carcinoid cells [45]. Similar effects have been reported for estradiol, ZM336372 and tautomycin [46-50]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Overdiagnosis of bronchopulmonary carcinoid tumors together with overtreatment can cause serious postoperative consequences for the patient. We report of a patient with a typical bronchopulmonary carcinoid tumor, which was initially misdiagnosed and treated as an adenocarcinoma of the lung. GnrH receptors and the associated Raf-1/MEK/ERK-1/2-pathway are potential targets for analogs in cancer treatment. We suspected a correlation between the lack of tumor growth, application of leuprolide and the Raf-1/MEK/ERK-1/2-pathway. Therefore, we examined GnrH receptor status in the examined specimen. In 2010 a 77 year-old male patient was shown to have a tumor mass of about 1.7 cm diameter in the inferior lobe of the left lung. Since 2005, this tumor had hitherto been known and showed no progression in size. The patient suffered from prostate cancer 4 years ago and was treated with TUR-P, radiation therapy and the application of leuprolide. We conducted an explorative thoracotomy with atypical segment resection. The first histological diagnosis was a metastasis of prostate cancer with lymphangiosis carcinomatosa. After several immunohistochemical stainings, the diagnosis was changed to adenocarcinoma of the lung. We conducted a re-thoracotomy with lobectomy and systematic lymphadenectomy 12 days later. The tumor stage was pT1 N0 MX G2 L1 V0 R0. Further immunohistochemical studies were performed. We received the results 15 days after the last operation. The diagnosis was ultimately changed to typical carcinoid tumor without any signs of lymphatic vessel invasion. The patient recovered well from surgery, but still suffers from dyspnea and lack of physical performance. Lung function testing revealed no evidence of impairment. The use of several immunohistochemical markers, careful evaluation of hematoxylin-eosin sections and the Ki-67 labelling index are important tools in discriminating between carcinoids and other bronchopulmonary carcinomas. Although we could not detect GnrH-receptors in the examined specimen, there may be individual differences in expression. GnrH receptor profiles in typical and atypical carcinoids should be scrutinized. This could lead to new therapeutical options, since the GnrH receptor has already been described on atypical carcinoids. Clinically tested drugs such as leuprolide could come to use.
    Full-text · Article · Jan 2012 · World Journal of Surgical Oncology
Show more